Performing meta-analysis with incomplete statistical information in clinical trials by Ma, JB et al.
BioMed Central
BMC Medical Research 
Methodology
ssOpen AcceResearch article
Performing meta-analysis with incomplete statistical information in 
clinical trials
Jianbing Ma*1, Weiru Liu1, Anthony Hunter2 and Weiya Zhang3
Address: 1School of Electronics, Electrical Engineering and Computer Science, Queen's University Belfast, Belfast, BT7 1NN, UK, 2Department of 
Computer Science, University College London, Gower Street, London, WC1E 6BT, UK and 3Academic Rheumatology, Medical & Surgical Sciences, 
City Hospital, Nottingham, NG5 1PB, UK
Email: Jianbing Ma* - jma03@qub.ac.uk; Weiru Liu - w.liu@qub.ac.uk; Anthony Hunter - a.hunter@cs.ucl.ac.uk; 
Weiya Zhang - weiya.zhang@nottingham.ac.uk
* Corresponding author    
Abstract
Background: Results from clinical trials are usually summarized in the form of sampling distributions.
When full information (mean, SEM) about these distributions is given, performing meta-analysis is
straightforward. However, when some of the sampling distributions only have mean values, a challenging
issue is to decide how to use such distributions in meta-analysis. Currently, the most common approaches
are either ignoring such trials or for each trial with a missing SEM, finding a similar trial and taking its SEM
value as the missing SEM. Both approaches have drawbacks. As an alternative, this paper develops and tests
two new methods, the first being the prognostic method and the second being the interval method, to
estimate any missing SEMs from a set of sampling distributions with full information. A merging method is
also proposed to handle clinical trials with partial information to simulate meta-analysis.
Methods: Both of our methods use the assumption that the samples for which the sampling distributions
will be merged are randomly selected from the same population. In the prognostic method, we predict the
missing SEMs from the given SEMs. In the interval method, we define intervals that we believe will contain
the missing SEMs and then we use these intervals in the merging process.
Results: Two sets of clinical trials are used to verify our methods. One family of trials is on comparing
different drugs for reduction of low density lipprotein cholesterol (LDL) for Type-2 diabetes, and the other
is about the effectiveness of drugs for lowering intraocular pressure (IOP). Both methods are shown to
be useful for approximating the conventional meta-analysis including trials with incomplete information.
For example, the meta-analysis result of Latanoprost versus Timolol on IOP reduction for six months
provided in [1] was 5.05 ± 1.15 (Mean ± SEM) with full information. If the last trial in this study is assumed
to be with partial information, the traditional analysis method for dealing with incomplete information that
ignores this trial would give 6.49 ± 1.36 while our prognostic method gives 5.02 ± 1.15, and our interval
method provides two intervals as Mean ∈ [4.25, 5.63] and SEM ∈ [1.01, 1.24].
Conclusion: Both the prognostic and the interval methods are useful alternatives for dealing with missing
data in meta-analysis. We recommend clinicians to use the prognostic method to predict the missing SEMs
in order to perform meta-analysis and the interval method for obtaining a more cautious result.
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Clinical trials are widely used to test new drugs or to com-
pare the effect of different drugs [2]. For example, many
clinical trials have been carried out to investigate the effi-
cacy of drugs for lowering intraocular pressure, such as tra-
voprost, bimatoprost, timolol, and latanoprost, [3-11],
and many to investigate the oral diabetes medication for
adults with Type-2 diabetes [12-17]. Given that there is a
huge number of trials available and reports on trials are
very time consuming to read and understand, a systematic
review of related trials is useful for medical practioners or
other health care professionals to obtain an overall esti-
mation about drugs/therapies of interest. Meta-analysis is
the technique commonly used to summarize related trials
results. Statistically, meta-analysis is in effect a process for
merging sampling distributions (see its explanation in
Preliminaries) into a single distribution.
When the full information of sampling distributions used
in the trials is available, merging the results from these tri-
als is usually a matter of systematic use of established
techniques from statistics. However, in reality, some trial
results reported in the literature are statistically incom-
plete. For instance, the standard error of mean (SEM) may
be missing from a sampling distribution. A clinical trial
with incomplete information is often abandoned, or, an
SEM from a similar trial is used to substitute the missing
data. Obviously, abandoning trials will decrease the
power of a meta-analysis since trials that are eligible for
analysis cannot be taken into account. On the other hand,
if these trials are considered and a missing SEM is replaced
by a substitute SEM, two major difficulties of this
approach are inevitable. First finding a similar trial can be
very difficult. Second there is no guarantee that there
exists a similar trial with full information. Furthermore,
measuring the similarity between trials is another issue
that must be addressed. Therefore, an appropriate method
is urgently needed to deal with sampling distributions
with missing information when considering meta-analy-
sis.
In this paper, we propose a prognostic method where
missing SEMs are predicted from known information
(SEMs) and an interval method where an interval is calcu-
lated in which the missing SEMs are assumed to be. These
two methods are based on the assumption that the sam-
pling distributions to be analyzed and merged are from
the same population by random selection. In a sense, the
two methods can be viewed as extremes. The prognostic
method uses an estimate of the missing SEM, while the
interval method aims at considering the best and worse
cases. Of course, there are other reasonable intermediate
procedures, for example, a Bayesian predictive approach is
a very natural tool for dealing with missing information.
Significantly, our methods can also be used in the process
of merging between group differences (almost all meta-anal-
ysis performs merging of between group differences). In
fact, our methods can be applied to any results obtained
from clinical trials, as long as these results (regarded as
random variables) theoretically follow a sampling distri-
bution.
Methods
Study examples
The study examples were drawn from two systematic
reviews [1,17]. [17] reported a meta-analysis on drugs for
patients with Type-2 diabetes and [1] reported a meta-
analysis on lowering intraocular pressure for patients with
open angle glaucoma or ocular hypertension.
In order to compare the results obtained from our meth-
ods with that from [17], we first attempted to collect all
the original information on sampling distributions from
each of the clinical trials papers used in [17]. After going
through these papers, we found that we could not get the
sampling distributions with full information from every
single paper, as some of these papers did not provide the
SEM values. We then applied our two methods to merge
these (including partial) distributions and compared the
merged result with that obtained in [17]. In contrast to
[17], in [1] every sampling distribution used has full sta-
tistical information. To test the adequacy of our methods
for dealing with missing information, we randomly
selected a trial from [1] and deleted its SEM value. We
then applied our two methods to recover this missing
SEM value before merging this trial with the rest. Finally,
we compared our results with that from [1].
Preliminaries
In statistics, a normal distribution associated with a ran-
dom variable is denoted as X ~ N (μ, σ2). For the conven-
ience of further calculations in the rest of the paper, we use
notation X ~ N (μ, σ) instead of X ~ N (μ, σ2) for a normal
distribution of variable X.
In statistics, random samples of individuals are often used
as the representatives of the entire group of individuals
(often denoted as a population) to estimate the values of
some parameters of the population. The mean of variable
X of the samples, when the sample size is reasonably large,
follows a normal distribution. This distribution is typi-
cally referred to as a sampling distribution.
We use X ~ N (μ, SEM) to denote a sampling distribution
with mean value μ and standard error of mean SEM.
The basic merging rule for sampling distributions is as fol-
lows.Page 2 of 11
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pling distributions, then the merged sampling distribu-
tion X ~ N (μ, SEM) is given by
Equation 1 can be easily induced from σ1 = σ2 where σi =
SEMi  and ni is the number of samples of the ith trial
(for i = 1, 2).
Conventionally, clinicians usually use notation
, thus Equation 1 can be rewritten as:
It is easy to see that the merging rule is associative, thus
this rule can be straightforwardly used to merge multiple
sampling distributions. Let Xi ~ N (μi, SEMi), 1 ≤ i ≤ k, then
for the merged sampling distribution X ~ N (μ, SEM), we
have
This is the classical merging method (i.e., meta-analysis)
used by clinicians.
The Prognostic Method
We propose a method to predict missing SEMs for sam-
pling distributions from other distributions that have
SEM values. Hereafter, we assume that there are k + l trials
altogether where k trials are with full information, i.e.,
(μ1, SEM1, n1),..., (μk, SEMk, nk)
and l trials with partial information, i.e.,
(μk+1, nk+1),..., (μk+l, nk+l).
We want to get the merging result of those k + l trials.
If we have both the SEM value and the sample size n from
a trial, then we can obtain σ by equation SEM = . Thus
for k trials with
(μ1, SEM1, n1),..., (μk, SEMk, nk)
we get σi = SEMi , 1 ≤ i ≤ k. Because it is assumed that
these trials randomly select samples from the same popu-
lation, these σis suggest what the real value σ could be. In
fact, from the well-known Error Theory, we can use
to replace the real σ. When k gets larger, σ* gets closer to
the real σ. Therefore, for a sampling distribution without
a standard error, we can use 
 as its standard error where 
 is the sample size of this sampling distribution.
To summarize, the prognostic method uses the following
equation to predict the missing 
 value for trial j with sample size 
, given that for k trials, each of which has the SEMi value
and the sample size ni.
Then we are able to use the standard meta-analysis
method to merge trials with predicted SEM values and tri-
als with full information.
The Interval Method
In contrast to estimating a single value for a missing SEM
as discussed above, in this section, we establish a method
to estimate a reliable interval for a missing SEM. Then we
propose the corresponding merging rule for this case.
For the k trials with
(μ1, SEM1, n1),..., (μk, SEMk, nk),
we have σi = SEMi , 1 ≤ i ≤ k. Let
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σmin and σmax. Therefore for a sampling distribution with-
out the standard error SEM*, we have
 where n* is the sample size of this
trial.
It remains for us to investigate how to use this interval
value for merging. For simplicity and illustration, first let
us consider the case where there is only one trial with a
missing SEM. Let μk denote the weighted average of μ1 toμk (the k trials with known SEMs), i.e.,
μk is equivalent to the merged mean value for the k trials
in meta-analysis. Let
and
then we have the following result.
Let Xi ~ N (μi, SEMi), 1 ≤ i ≤ k, denote the ith sampling dis-
tribution with sample size ni and Xi+1 ~ N (μi+1, SEMi+1)
denote the (k + 1)th sampling distribution with sample
size ni+1 where value SEMi+1 is unknown. Then the merged
result N (μ, SEM) of the interval method is:
1. If μk+1≤ μk, then μ ∈ [ , ]
2. If μk+1 > μk, then μ ∈ [ , ]
and
The corresponding bounds of interval for μ depend on
whether μk+1 is larger or smaller than μk. If μk+1 is not big-
ger than μk, then the lower (resp. upper) bound of its
interval  (resp. ) is obtained from the result of
merging k + 1 trials by the traditional meta-analysis
method where the (k + 1)th SEM is assumed to be
. On the other hand, if μk+1 is larger
than μk, then the lower (resp. upper) bound is obtained
from the result of merging k + 1 trials by the traditional
meta-analysis method where the (k + 1)th SEM is assumed
to be 
Similarly, for l trials with incomplete statistical informa-
tion, we define
and
∀i, k + 1 ≤ i ≤ k + l, we let
and
then we have the following result.
Let Xi ~ N (μi, SEMi), 1 ≤ i ≤ k + l, denote the ith sampling
distribution with sample size ni such that SEMi is assumed
missing when i > k, then the merged result N (μ, SEM)
applying the interval method to these k + l trials is:
and
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In clinical trials, the between group difference of two drugs/
therapies about two groups is frequently used. Suppose
that the numbers of patients in the two groups are the
same (majority of clinical trials allocate (approximately)
the same number of patients in two contrast groups) and
we denote this number as n. Assume that the first group
gives a sampling distribution of the effect of one drug as
X1 ~ N (μ1, SEM1) and the second group about another
drug as X2 ~ N (μ2, SEM2). Conventionally, the between
group difference (of the two drugs involved) is calculated
as
Thus we get
Let  be a fixed value since σ1 and σ2 are
fixed by the selected populations, we get SEM = .
Therefore, the two methods proposed in the previous sec-
tions are also suitable in the process of merging the
between group differences.
Results and discussion
Case Study of Drugs for Type-2 Diabetes
In this section, we use the data from clinical trials on med-
ication for adults with Type-2 diabetes as our first case
study.
Many research papers and reports have been published to
show the effectiveness of various oral medication for
Type-2 diabetes ([12-16], etc.). For oral medication of
Type-2 diabetes, the meta-analysis in [17] compared each
pair of drugs on systolic blood pressure (SBP for short),
diastolic blood pressure (DBP), low density lipoprotein
cholesterol (LDL-C) and high density lipoprotein choles-
terol (HDL-C), etc.
In this section, we consider the between group difference
on the effectiveness of pairs of drugs for lowering LDL-C.
In [17], there were 14 sets of results comparing between
group difference of 14 pairs of drugs on lowering LDL-C.
We selected four sets among these 14 sets for our case
study, because each of them contains more than four trials
so that our merging method can be applied more ade-
quately. Our data were obtained from the original papers,
most of which are the same as the data used in [17], how-
ever some data used in [17] are different from what we
have found in the original papers. When this happens, we
will state it clearly in the examples.
The drugs being compared in the selected four groups are
1. Thiazolidinedione versus Metformin (Example 1),
2. Triazolidinedione versus second generation Sulfonylu-
reas (Example 2),
3. Metformin versus Metformin plus second generation
Sulfonylureas (Example 3),
4. Second generation Sulfonylureas versus Metformin
plus second generation Sulfonylureas (Example 4).
Example 1 Drugs for reduction of low density lipoprotein
(LDL for short) were studied by many papers. They compared
the LDL-C reduction between different trial groups. For exam-
ple, to compare drugs Thiazolidinedione and Metformin, we
obtained the following (in mg/dL) sampling distributions from
four trials.
[18]: XPa ~ N (13.3, SEMPa) with n = 102.
[12]: XLT ~ N (7.8, 20.5) with n = 20.
[19]: XHan ~ N (10.1, 2.7) with n = 320.
[20]: XSch ~ N (15.2, SEMSch) with n = 597.
Here n is the size of samples (number of patients) in each group
of the trial, and SEMPa and SEMSch stand for the missing values
(SEM values) from their respective trials data.
The meta-analysis results obtained by using prognostic method,
interval method, and traditional method for incomplete trials
information are provided in Table 1.
In Table 1, the first column shows the SEMs of XPa and XSch are
missing. The second column shows that the result obtained by
the prognostic (P for short) method is Xp ~ N (12.56, 1.91)
(denoted as 12.56 ± 1.91 in Table 1). The third column
stands for the result obtained by the interval method (Int for
short) and the last column stands for the result given by the tra-
ditional method on meta-analysis with incomplete trials infor-
mation (Inc for short), i.e., removing trials with incomplete
information. The rest of the tables in this case study follow the
same notations and explanations.
X N SEM SEM~ ( , ).μ μ1 2 12 22− +
SEM SEM SEM
n
= + =
+
1
2
2
2 1
2
2
2σ σ
.
σ σ σ= +1
2
2
2
σ
n
Table 1: Thiazolidinedione vs. Metformin
Missing P Int Inc
(XP) (XI) (XInc)
XPa, XSch 12.56 ± 1.91 [11.94, 13.39] ± [1.54, 2.14] 10.1 ± 2.68Page 5 of 11
(page number not for citation purposes)
BMC Medical Research Methodology 2008, 8:56 http://www.biomedcentral.com/1471-2288/8/56Compared to XBW ~ N (12.5,1.89) [17]which is the meta-
analysis result when all information is complete, obviously, with
two SEM values missing, XP is still very close to XBW . Therefore,
XP can be used to replace XBW  for this set of trials. In addition,
we also have 12.5 ∈ [11.94, 13.39] and 1.89 ∈ [1.54, 2.14]
which indicate that XI is a good estimation.
Example 2 To compare Thiazolidinedione and second genera-
tion Sulfonylureas, we obtained the following sampling distri-
butions (in mg/dL) from five trials.
[12]: XLT ~ N (10.5, 14.44) with n = 20.
[13]: XCM ~ N (11.31, 1.59) with n = 620.
[14]: XTJ ~ N (6.63, SEMTJ) with n = 100.
[15]: XPM ~ N (5, 6.04) with n = 86.
[16]: XMC ~ N (14.6, SEMMC) with n = 315.
There are two missing SEM values.
The meta-analysis results for this example are provided in
Table 2.
In this example, XP is reasonably close to XBW where XBW ~ N
(10.4,1.61) [17]. However XInc is closer.
Example 3 To compare Metformin and Metformin plus second
generation Sulfonylureas, we looked at another set containing
six trials with sampling distributions as follows (in mg/dL).
[21]: XGa ~ N (-10.2, SEMGa) with n = 168.
[22]: XGo ~ N (-7.0, 5.18) with n = 60.
[23]: XMa ~ N (-3.9, 4.11) with n = 103.
[24]: XDeF ~ N (2.0, 2.8) with n = 186.
[25]: XH94 ~ N (-3.1, 3.6) with n = 30.
[26]: XH91 ~ N (8.2, 5.8) with n = 15.
There is only one missing SEM value. The meta-analysis result
in [17] is XBW ~ N (-1.6, 2.53) while we obtained the follow-
ing results.
The meta-analysis results for this example are provided in
Table 3.
Some data (sampling distributions of [23,25,26]) used in [17]
are somehow different from the data we found from the original
papers. Naturally, there is a margin between the merged sam-
pling distribution from our methods and that from the meta-
analysis. Therefore, it is difficult to compare these results.
Example 4 A set of seven trials was analyzed in [17] to com-
pare the second generation Sulfonylureas versus Metformin plus
second generation Sulfonylureas. We obtained the following
seven sampling distributions (in mg/dL) from them.
[21]: XGa ~ N (-2.2, SEMGa) with n = 168.
[22]: XGo ~ N (-0.2, 4.6) with n = 60.
[23]: XMa ~ N (3.9, 4.72) with n = 103.
[27]: XGr ~ N (10.14, 10.17) with n = 87.
[24]: XDeF ~ N (11.0, 2.83) with n = 186.
[25]: XH94 ~ N (7.41, 4.22) with n = 30.
[26]: XH91 ~ N (19.89, 5.54) with n = 15.
There is one SEM value missing. The results from our methods
are given in Table 4.
It appears that XP is not so close to XBW where XBW ~ N
(8.1,2.55) [17]. Once again, some data (sampling distribu-
tions of [23,25,26]) used in [17] are not the same as given in
the original papers. So effectively, we had to use different data
to perform the merging of these several trials.
Table 2: Triazolidinedione vs. second generation Sulfonylureas
Missing P Int Inc
(XP) (XI) (XInc)
XTJ, XMC 11.35 ± 1.32 [10.91, 11.88] ± [1.20, 1.38] 10.9 ± 1.53
Table 3: Metformin vs. Metformin plus second generation 
Sulfonylureas
Missing P Int Inc
(XP) (XI) (XInc)
XGa -3.82 ± 1.43 [-6.11, -2.88] ± [1.15, 1.53] -0.73 ± 1.74
Table 4: Second generation Sulfonylureas vs. Metformin plus 
second generation Sulfonylureas
Missing P Int Inc
(XP) (XI) (XInc)
XGa 6.20 ± 1.57 [2.79, 7.96] ± [1.21, 1.73] 8.56 ± 1.78Page 6 of 11
(page number not for citation purposes)
BMC Medical Research Methodology 2008, 8:56 http://www.biomedcentral.com/1471-2288/8/56Case Study of IOP Reduction
In the above subsection, we applied our methods to
approximate the traditional meta-analysis when some
SEM values are missing. Because some of the data we
found in the original papers are different from that used
in the meta-analysis paper [17], it is hard to judge our
approaches in some cases. In order to further validate our
approaches experimentally, in this section, we consider
and apply our methods to a set of trials with full statistical
information. In other words, every trial we consider will
have both the mean and the SEM value in its sampling dis-
tribution. To validate how accurate our two approaches
are for predicting an SEM value, we deleted an SEM value
from a trial selected randomly from a set of trials, and
applied our methods to predict it. We then applied the
meta-analysis method to merge the trial with the pre-
dicted SEM value together with the rest of trials in the
group to see how close this new result is to the original
meta-analysis result. Furthermore, as the traditional
method for trials with incomplete information always
abandons trials with incomplete information, we also
compared our methods with this traditional method.
We considered four sets of trials used in [1] on IOP reduc-
tion. [1] reported the meta-analysis of some trials about
between group difference of IOP reduction from baselines
using drugs Latanoprost and Timolol.
Example 5 (one week results) Three papers on clinical trials
about IOP reduction gave the following three sampling distri-
butions comparing Latanoprost and Timolol for one-week trial
duration.
[28]: X1 ~ N (8.5, 8.24) with n = 46.
[29]: X2 ~ N (5.62, 7.91) with n = 15.
[30]: X3 ~ N (6.85, 4.01) with n = 20.
The traditional meta-analysis in [1] produced X1w ~ N (6.90,
3.28). We deleted the SEM value from one of these trials in
turn and applied our methods to predict it. Then we calculated
the merged sampling distribution involving this predicted SEM
value. The results are summarized in Table 5.
In Table 5, the second row starting with "X1" means that if the
SEM value of X1 is missing, then from the prognostic method,
we get  ~ N (7.55, 2.53), from the interval method, we get
 ~ N ([7.33, 7.83], [2.12, 2.80]), and from the traditional
method for trials with incomplete information, we get  ~
N (6.60, 3.57). Other rows are explained similarly. We can
see that s, 1 ≤ i ≤ 3, are close to the result obtained by the
traditional method.
Example 6 (one month results) Three papers on clinical trials
about IOP reduction gave the following three sampling distri-
butions comparing Latanoprost and Timolol for one month
duration.
[28]: X1 ~ N (11.0, 6.05) with n = 46.
[31]: X2 ~ N (5.2, 1.66) with n = 184.
[32]: X3 ~ N (0.4, 2.17) with n = 294.
The traditional meta-analysis gives X1m ~ N (3.77, 1.29). The
results are summarized in Table 6. s, 1 ≤ i ≤ 3, are also very
close to the result obtained by the traditional method.
Example 7 (three months results) Five papers on clinical trials
about IOP reduction gave the following five sampling distribu-
tions comparing Latanoprost and Timolol for three months
duration.
[33]: X1 ~ N (4.0, 3.11) with n = 267.
[34]: X2 ~ N (5.41, 5.56) with n = 60.
[35]: X3 ~ N (3.2, 4.03) with n = 36.
X P
1
X I
1
X Inc
1
X P
i
X P
i
Table 5: Latanoprost vs. Timolol: one week
Missing P Int Inc
X1 7.55 ± 2.53 [7.33, 7.83] ± [2.12, 2.80] 6.60 ± 3.57
X2 6.97 ± 3.37 [6.58, 7.07] ± [2.84, 3.49] 6.85 ± 4.01
X3 6.96 ± 4.91 [6.94, 6.97] ± [4.38, 5.19] 7.00 ± 5.71
X P
i
X I
i
X Inc
iPage 7 of 11
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[32]: X5 ~ N (1.9, 2.12) with n = 294.
The traditional meta-analysis gives X3m ~ N (3.52, 1.44). The
results are summarized in Table 7. Once again, s, 1 ≤ i ≤
5, are close to the result obtained by the traditional method.
Example 8 (six months results) Four papers on clinical trials
about IOP reduction gave the following four sampling distribu-
tions comparing Latanoprost and Timolol for six months dura-
tion.
[33]: X1 ~ N (4.8, 3.14) with n = 267.
[36]: X2 ~ N (7.1, 1.58) with n = 268.
[35]: X3 ~ N (4.5, 5.23) with n = 36.
[32]: X4 ~ N (1.5, 2.14) with n = 294.
The traditional meta analysis gives X3m ~ N (5.05, 1.15). The
results are summarized in Table 8. Finally, s, 1 ≤ i ≤ 4, are
also close to the result obtained by the traditional method.
By comparing these results, we can conclude that the more
trials we have in an example, the closer our result is to the
traditional meta-analysis method. This is because when
the number of trials included in a meta-analysis gets
larger, the error of meta-analysis gets smaller. Therefore,
the predicted SEM value from the prognostic method gets
closer to the real SEM value and the intervals used in the
interval method have a better chance to contain the real
values.
Discussion
Here we mainly analyze the results obtained from the IOP
examples. Since we have stated that some data used in
[17] are different from the data we found in the original
papers, it would be difficult to compare those results
objectively.
First, we found that the results obtained from the prog-
nostic method are closer to the true results. It implies that
the prognostic method is truly applicable. Although the
interval method gives an interval instead of a single value,
the interval provides a clear indication as to where the real
value could be, and so it is an alternative to supplement
the missing value.
Second, we found that the prognostic method is superior
to the traditional method for trials with incomplete infor-
mation which abandons trials with missing information.
In fact, we can see that although in some cases, the results
obtained by the traditional method for trials with incom-
plete information are also close to the true results, in some
other cases, they deviate from the true results significantly,
such as cases like in Table 6, when the SEM of X2 is miss-
ing, in Table 7, that of X4 or X5 is missing, and in Table 8,
that of X2 or X4 is missing. That is, the prognostic method
X P
i
X P
i
Table 6: Latanoprost vs. Timolol: one month
Missing P Int Inc
X1 4.05 ± 1.26 [3.84, 4.46] ± [1.22, 1.28] 3.43 ± 1.32
X2 2.81 ± 1.67 [2.73, 2.89] ± [1.64, 1.69] 1.61 ± 2.04
X3 3.38 ± 1.21 [2.49, 4.00] ± [1.01, 1.33] 5.61 ± 1.60
X P
i X I
i
X Inc
i
Table 7: Latanoprost vs. Timolol: three months
Missing P Int Inc
X1 3.58 ± 1.35 [3.51, 3.72] ± [1.09, 1.46] 3.39 ± 1.62
X2 3.53 ± 1.43 [3.47, 3.76] ± [1.34, 1.46] 3.38 ± 1.49
X3 3.55 ± 1.51 [3.54, 3.56] ± [1.49, 1.52] 3.57 ± 1.54
X4 3.99 ± 1.36 [3.59, 4.98] ± [1.17, 1.43] 2.88 ± 1.54
X5 3.77 ± 1.54 [2.93, 4.07] ± [1.14, 1.66] 4.91 ± 1.96
X P
i X I
i
X Inc
iPage 8 of 11
(page number not for citation purposes)
BMC Medical Research Methodology 2008, 8:56 http://www.biomedcentral.com/1471-2288/8/56is more stable and precise than the traditional method for
incomplete trial information. This result is not surprising
because the prognostic method takes into account all the
eligible trials. On the contrary, if the SEM value of a trial
with a large/small mean value is missing, then the tradi-
tional method for trials with incomplete information will
abandon this trial and naturally gets a result with smaller/
higher mean value than the true one. However, the prog-
nostic method does not abandon this trial, and instead it
predicts a value for the missing one. Therefore, the final
combined result is closer to the real result of meta-analy-
sis. This is also illustrated by Examples 5,6,7,8, etc, except
the case of the missing SEM of X1 in Example 5.
Dealing with missing data in statistics, especially in meta-
analysis is a very important issue (e.g., [37-39]). However,
there are hardly any papers focusing on missing standard
errors. This paper thus provides some fresh results about
how to deal with this situation. Our assumption that the
populations should be the same or similar intuitively fol-
lows the well known Missing-at-random (MAR) assump-
tion, except that MAR mainly focuses on repeatedly
measured data while ours are focusing on different trials.
With this assumption, the prognostic and the interval
methods are easily induced. Generally speaking, the prog-
nostic method is related to the regression imputation and
the interval method is to some extent a concrete imple-
mentation of the best/worst case analysis [40] with our
assumption and situations.
A small caveat of the prognostic and the interval methods
is that when the input data are imprecise (as shown in
Examples 3 and 4), we may obtain worse results than that
from the traditional method for incomplete information.
This is because when some input data are imprecise, the
prognostic method will get wrong predictions for missing
SEMs, hence obtain worse meta-analysis results whilst the
traditional method for incomplete trial information sim-
ply abandons trials with incomplete information, avoid-
ing any wrong predictions and therefore may obtain
better results. In addition, in Example 5, when the SEM
value of X1 is missing, we found that the result obtained
by the prognostic method is not as accurate as that
obtained by the traditional method for incomplete infor-
mation. This is because the SEM value of X1 is exception-
ally larger than the others, i.e., as the sample size of X1 is
greater than those of X2 and X3, it is expected (according
to our assumption of same population) that the SEM of X1
should be smaller, however, it is not. So the prognostic
method performs less effectively here.
Conclusion
Methods to deal with statistical information in clinical tri-
als for which the SEMs values are missing is a neglected
area in the literature. An obvious solution is to ignore a
trial with missing SEM values. Our methods provide an
application tool to solve this problem by effectively pre-
dicting missing SEMs or providing applicable intervals for
the missing SEMs. The prognostic method can be used to
obtain a result in a commonly accepted format, e.g., sam-
pling distribution, whilst the interval method, although
seemingly not so straightforward, provides a safer and
also informative result.
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